HUTCHMED (China) Limited (HCM) Cash Flow Statement

The OCF/NI ratio of 0.77 in 2026Q2 indicates that reported net income is not fully translating into cash, likely due to accruals and timing differences. In contrast, 2025Q4 showed an OCF/NI of 4.21, but that quarter's net income was only $977.5K, making the ratio less meaningful. The 2025Q1-Q2 period saw negative OCF despite net income of $227.5M, highlighting the lumpy nature of licensing payments and the disconnect between accounting income and cash generation.

The FCF margin improved from -29.6% in 2025Q1 to 2.4% in 2026Q2, but this is a recovery from a trough, not a sustainable trend. The 2024Q4 FCF of $16.3M (10.0% margin) was followed by two quarters of negative FCF, indicating that cash flows are highly sensitive to the timing of milestone payments. Investors should monitor whether the recent positive FCF can be maintained without another large upfront payment.

The low capital intensity is consistent with a biotech model that outsources manufacturing and relies on partners for commercialization. However, the negative CapEx figures in some quarters (e.g., -$2.8M in 2026Q1) may indicate asset sales or lease adjustments, which could distort the true maintenance capex requirement. Given the company's focus on R&D, the modest capex appears adequate for current operations, but investors should watch for any increase if the company expands its own manufacturing capabilities.

The positive working capital contribution in recent quarters may reflect improved collections or delayed payments, but the large negative swings in 2024 and 2025 suggest that milestone receipts and related receivables create lumpy cash flows. The $8.5M positive working capital change in 2025Q3-Q4 helped offset weak operating income, but this is not a reliable source of cash. Management's ability to manage receivables and payables will be critical given the thin cash position.

The absence of shareholder returns suggests management is prioritizing cash preservation for R&D and potential milestone obligations. The $18.0M buyback in early 2024 was modest relative to market cap and may have been opportunistic. With a cash balance of only $71M, the company appears to be conserving resources, which is prudent given the negative operating cash flow in several quarters. Investors should monitor whether any future capital deployment shifts toward debt reduction or pipeline investment.

The divergence is primarily driven by the $227.5M net income quarters in 2025, which likely included non-cash gains from licensing deals, while operating cash flow was negative. This suggests that reported profitability is not a reliable indicator of cash-generating ability. The cumulative gap of over $500M warrants close scrutiny, as it implies that earnings are heavily reliant on accruals and one-time items. Investors should focus on cash burn rates and the sustainability of operating cash flow without milestone infusions.